This bill, the "Most Favored Patient Act of 2026", sponsored by Rep. Dan Meuser (R-PA), requires the Center for Medicare and Medicaid Innovation to test a five-year most-favored-nation drug pricing model beginning January 1, 2029. Under the model, certain drug manufacturers would have to provide access to a most-favored-nation price for covered drugs to eligible Medicare and Medicaid patients, pharmacies, mail-order services, hospitals, physicians, and other providers. The bill defines that price based on the second-lowest net price for the drug among reference countries including Canada, France, Germany, Japan, Switzerland, and the United Kingdom.

Lowering drug costs is important, but this bill relies on the wrong tool: foreign reference pricing run through Washington. Instead of fixing PBM abuses, rebate games, and the other middlemen driving up drug costs, the bill ties American prices to countries that use government price controls and ration access to new treatments. That risks importing the same broken incentives into Medicare and Medicaid while threatening the innovation pipeline patients depend on for future cures.

This bill, the "Great American Healthcare Plan", sponsored by Rep. Eric Burlison (R-MO), is a broad healthcare reform package that expands access to Health Savings Accounts, increases HSA contribution limits, allows HSA funds to be used for more healthcare and wellness expenses, and lets certain HSA contributions satisfy the employer mandate. The bill also creates health marketplace pools to help individuals and small businesses access group-style coverage, strengthens hospital and insurer price transparency, requires clearer itemized bills and explanations of benefits, and includes provisions related to access to prescription drugs and complex therapies.

This bill takes the right approach by putting patients and families back in control of their healthcare dollars. Instead of doubling down on Obamacare subsidies, mandates, and Washington-run coverage, it expands flexible savings tools, gives smaller employers and individuals more purchasing power, and forces more of the system to show real prices before patients get the bill. More choice, more transparency, and more patient control are exactly the reforms needed to bring down premiums and make healthcare less expensive.

This bill, the "Maternal Health Pandemic Response Act", sponsored by Rep. Lauren Underwood (D-IL), authorizes $190 million for federal data collection, surveillance, and research on maternal and infant health during public health emergencies. The bill funds CDC programs, maternal mortality surveillance, PRAMS survey expansion, and NIH research, while also directing federal agencies to publish emergency maternal health data, run public health education campaigns, and create a new HHS task force on maternity care during public health emergencies.

While maternal and infant health are important priorities, this bill responds with more federal spending, more federal reporting systems, and another Washington task force. Instead of focusing on removing barriers that make maternity care harder to access, the bill expands the public health bureaucracy and uses emergency response as a vehicle for new programs and future federal recommendations on how care should be delivered. This is exactly the kind of open-ended federal expansion that drives taxpayer costs higher without fixing the underlying affordability problems in healthcare.

This bill, the "Lainie Jones Comprehensive Cancer Survivorship Act of 2026", sponsored by Rep. Debbie Wasserman Schultz (D-FL), creates new federal programs and coverage requirements around cancer survivorship care. The bill adds Medicare coverage for cancer care planning and coordination services, directs HHS to develop an alternative payment model for cancer survivorship care under Medicare and Medicaid, establishes employment assistance and survivorship grant programs, expands Medicaid and CHIP coverage for childhood cancer transition services and cancer fertility services, and creates an Office of Cancer Survivorship within the National Cancer Institute.

Cancer survivors deserve strong support, but this bill takes the usual Washington approach of creating new benefits, new grants, new offices, and new federal payment models. Instead of focusing on lowering treatment costs, expanding choice, or removing barriers to care, the bill grows the federal healthcare bureaucracy and adds new taxpayer obligations across Medicare, Medicaid, CHIP, HHS, Labor, and NCI. More federal programs may sound compassionate, but they also mean more spending, more mandates, and more government control over how care is organized and paid for.

This bill, the "Our Doctors First Act of 2026", sponsored by Rep. Greg Steube (R-FL), amends Medicare graduate medical education payment rules to prohibit federal payments for residency training costs tied to individuals who are not U.S. citizens or nationals. Hospitals and qualified nonhospital providers that knowingly count non-citizen residents for Medicare GME payment purposes would face escalating penalties, including civil monetary penalties and exclusion from GME payments for repeat violations.

This bill is about making sure limited, taxpayer-funded medical training dollars are used to strengthen America's physician workforce first. Communities across the country are facing doctor shortages, while American medical graduates take on heavy debt and compete for limited residency slots. By ensuring Medicare-funded residency support prioritizes U.S. doctors, the bill helps direct federal healthcare dollars toward expanding access for American patients instead of subsidizing training pathways for non-citizens who may leave the country after their training.

This bill, the "Healthcare Freedom and Fairness Act", sponsored by Rep. Beth Van Duyne (R-TX), amends ERISA to allow qualified health marketplace pools to offer group health plans or group health insurance coverage. These pools would let small businesses, self-employed workers, underinsured Americans, and other eligible members join together into larger risk pools, including nationwide pools, to negotiate for more affordable coverage options. The bill also gives these pools flexibility to offer prescription drug and over-the-counter drug coverage, including as a standalone benefit.

This is a practical way to give smaller employers and independent workers some of the same purchasing power that large employers already have. Instead of leaving families stuck with expensive Obamacare plans or pushing them toward more government subsidies, the bill removes barriers that make it harder for people to band together and shop for coverage that works for them. More pooling, more competition, and more flexibility are exactly the kinds of reforms needed to bring premiums down.